Clinical Trials Browser

Phase 3 × INDUSTRY × Natalizumab × Clear all

NCT01416181 2017-09-11

ASCEND in SPMS

Phase 3 Terminated

889 enrolled 31 charts

Multiple Sclerosis, Neoplasm Metastasis, Multiple Sclerosis, Chronic Progressive